Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.15    -0.005 (-3.23%)
Bid:
0.14
Ask:
0.16
Spread: 0.02 (14.286%)
Market Cap: £1.98m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Final Results

29 Jun 2006 12:20

Azure Holdings PLC29 June 2006 Azure Holdings plc REPORT AND FINANCIAL STATEMENTS For the year ended 31 December 2005 CHAIRMAN'S STATEMENT I am pleased to present my first Chairman's statement for the year ended 31December 2005. In the year to 31 December 2005 the Company announced a loss after taxation of£134,000 (2005: £345,000). My predecessor mentioned in his last Chairman's statement that the Company wascontinuing to seek an acquisition and I am pleased we have a target and that thetransaction is moving forward. Your Company not only has a new Board but also a new Nominated Adviser andBroker and we are all working together to bring the proposed transaction to amutually satisfactory conclusion. All parties are aware of the need to complete the transaction by the end ofSeptember and at the time of writing we remain on target to do so. Barry Gold Chairman 29 June 2006 AZURE HOLDINGS PLC PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2005 2005 2004 Note Total Total £'000 £'000 Administrative expenses (134) (345) OPERATING LOSS (134) (345) LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION (134) (345) Taxation - - LOSS ON ORDINARY ACTIVITIES AFTER TAXATION (134) (345) LOSS PER SHARE 3 (0.28p) (0.86p) FULLY DILUTED LOSS PER SHARE 3 (0.28p) (0.86p) The Company has no recognised gains or losses other than the loss for the year. All activities are classed as continuing. AZURE HOLDINGS PLC BALANCE SHEET AT 31 DECEMBER 2005 2005 2004 £'000 £'000 CURRENT ASSETSDebtors 1 7Cash at bank and in hand 1 14 2 21CREDITORS: amounts falling due within one year (205) (90) NET CURRENT LIABILITIES (203) (69) TOTAL ASSETS LESS CURRENT LIABILITIES (203) (69) CAPITAL AND RESERVES Called up share capital 5,475 5,475Share premium account 10,279 10,279Profit and loss account (15,957) (15,823) EQUITY SHAREHOLDERS' FUNDS (203) (69) AZURE HOLDINGS PLC CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2005 2005 2004 £'000 £'000 CASH OUTFLOW FROM OPERATING ACTIVITIES (63) (225) FINANCING Issue of equity shares - 120Loans 50 - DECREASE IN CASH IN THE YEAR (13) (105) AZURE HOLDINGS PLC NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2005 1. Basis of preparation The financial information in this announcement does not constitute statutory financial statements as defined in Section 240 of the Companies Act 1985. The information relating to the year ended 31 December 2004 is an extract from the statutory accounts for that year, which have been delivered to the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain any statements under section 237(2) or (3) of the Companies Act 1985. The auditors have indicated that they will issue an unqualified report on the statutory financial statements for the year ended 31 December 2005. Copies of the Company's Report and Financial Statements will be despatched to shareholders on 29 June 2006 and will be available at the registered office of the Company: One Great Cumberland Place, London W1H 7AL. 2. Going Concern The financial statements have been prepared on the going concern basis. During the year the company incurred a loss of £134,000 and had net liabilities at 31 December 2005 of £203,000. Since the year end, the company has raised £398,000 via the issue of convertible loan stock. The directors continue to actively seek a suitable target for a reverse acquisition. The directors have therefore prepared the financial statements on the going concern basis. The financial statements do not include any adjustments that might arise if this basis was inappropriate. 3. Loss per share Loss per share are calculated using the loss on ordinary activities and the weighted average number of shares detailed below. In calculating fully diluted loss per share, the weighted average number of shares is adjusted for the effect of dilutive share options issued under Company share option schemes. 2005 2004 £'000 £'000 Basic and diluted loss attributable to ordinary (134) (345) shareholders Number Number Weighted average number of ordinary shares 48,317,569 39,767,965 Dilutive share options - - Adjusted weighted average number of ordinary 48,317,569 39,767,965 shares Loss per share (0.28p) (0.86p) Fully diluted loss per share (0.28p) (0.86p) 4. Reconciliation of Operating Loss to Net Cash 2005 2004 Outflow from Operating Activities £'000 £'000 Operating Loss (134) (345) Decrease in debtors 6 - Increase in creditors 65 31 Creditor settled via issue of shares - 89 Net cash outflow from operating activities (63) (225) 5. Reserves Share premium Profit and loss Total account account £'000 £'000 £'000 At 1 January 2005 10,279 (15,823) (5,544) Loss for the year (134) (134) At 31 December 2005 10,279 (15,957) (5,678) 6. Taxation Factors affecting taxation: The tax charge for the year does not equate to the loss before tax at the standard rate of corporation tax in the United Kingdom (30%). The differences are explained below: 2005 2004 £'000 £'000 Loss on ordinary activities before taxation (134) (345) Loss on ordinary activities multiplied by the (40) (104) standard rate of corporation tax in the United Kingdom of 30% (2004:30%) Effect of non-deductible expenses and addition 40 104 to tax losses As 31 December 2005, the Company had accumulated tax losses of £950,000 (2004:£817,000) arising from management expenses and £1,477,000) of capital losses. A deferred tax asset has not been recognised in respect of these losses as they are not expected to be used in the foreseeable future. 7. Dividends The directors are not proposing the payment of a dividend in respect of the year ended 31 December 2005. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Feb 201111:38 amRNSTotal Voting Rights
31st Jan 20117:00 amRNSFurther re Sale of Belgian Subsidiary, ValiBIO SA
27th Jan 20117:00 amRNSIssue of Equity
26th Jan 201110:58 amRNSResult of General Meeting
11th Jan 20117:00 amRNSPublication of Circular and Notice of GM
2nd Dec 20107:00 amRNSUpdate - Eurostars Programme
1st Dec 20107:00 amRNSTotal Voting Rights
10th Nov 20107:00 amRNSIssue of equity and update
1st Nov 20104:12 pmRNSTotal Voting Rights
29th Oct 20103:16 pmRNSIssue of Equity
29th Oct 20103:15 pmRNSChange of Adviser
11th Oct 201010:51 amRNSCompletion of Disposal
30th Sep 20102:17 pmRNSHalf Yearly Report
23rd Sep 20107:00 amRNSDisposal
31st Aug 20107:00 amRNSTotal Voting Rights
16th Aug 20105:12 pmRNSIssue of Equity
12th Aug 20107:00 amRNSLicensing Deal with Cancer Research Technology
15th Jul 20107:00 amRNSHPV Test Starts Clinical Validation
30th Jun 201010:15 amRNSResult of AGM
17th Jun 20107:00 amRNSEurostars' GeneICE Programme - First Year Review
17th Jun 20107:00 amRNSGeneICE Update
24th May 20107:00 amRNSRe Agreement
30th Apr 20102:47 pmRNSTotal Voting Rights
21st Apr 20104:08 pmRNSIssue of Equity - Replacement
21st Apr 20103:14 pmRNSResult of General Meeting
1st Apr 20103:19 pmRNSProposed reorg of share capital & Gen Meeting
1st Apr 201010:06 amRNSIssue of Equity
1st Apr 201010:06 amRNSTrading Update
31st Mar 20107:00 amRNSTotal Voting Rights
17th Mar 20107:00 amRNSSales and Distribution Agreement
15th Mar 201011:07 amRNSValiRx announces good stability data for VAL201
9th Mar 20107:00 amRNSFunding and Partnership Agreement
5th Mar 20103:00 pmRNSIssue of Equity
26th Feb 20104:30 pmRNSTotal Voting Rights
16th Feb 20109:00 amRNSIssue of Equity
29th Jan 201010:10 amRNSTotal Voting Rights
19th Jan 20107:00 amRNSGeneICE Update
13th Jan 20107:56 amRNSIssue of Equity
31st Dec 20098:03 amRNSIssue of Equity
30th Dec 20091:57 pmRNSResult of General Meeting
22nd Dec 200912:19 pmRNSRegional Funding
11th Dec 20097:42 amRNS?3m Equity Purchase Agreement
4th Dec 200910:14 amRNSNotice of General Meeting
25th Nov 20097:00 amRNSTrading Update
28th Sep 20097:40 amRNSHalf Yearly Report
14th Sep 20097:00 amRNSNew Distribution Venture & Trading Platform Launch
29th Jul 20098:06 amRNSAustralian Patent Acceptance
3rd Jul 200910:57 amRNSResult of AGM
10th Jun 20091:35 pmRNSFinal Results
10th Jun 20098:50 amRNSAward for cancer therapeutics project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.